China Plasma Protein Market: Trends and Opportunities (2015-2019)

  • ID: 3340098
  • Report
  • Region: China
  • 66 Pages
  • Daedal Research
1 of 4
The report titled “China Plasma Protein Market: Trends and Opportunities (2015-2019)” analyzes the potential opportunities, challenges, demand drivers and significant trends representing the Plasma Protein market in China. The report elucidates facts on theChina Plasma Proteins Market as supplemented by the latest available statistics.

The report gives valuable insight into technology used in China Plasma Proteins market, its demand and supply. It also profiles and analyzes the leading five companies operating in this industry with latest data and a brief overview of their business and finance structure along with a brief discussion of their future business strategies.

The report tries to study the growth pattern in the production and revenue earned by the China Plasma Protein companies and the latest trends concerning China Plasma Proteins. Most importantly, we have analyzed the current market size and project future market size of the overall China Plasma Protein market for the years to come.

Products Covered
- Albumin
- IVIG
- FactorVIII

Company Coverage

- China Biologic Product
- Hualan Biological Engineering
- Beijing Tiantan
- Shanghai RAAS Blood Products
- CSL Ltd.

Executive Summary

Plasma proteins, also termed as Serum Proteins or Blood Proteins, are proteins present in blood plasma. They serve different functions, including transport of lipids, hormones, vitamins and minerals in the circulatory system and the regulation of acellular activity and functioning of the immune system. Other blood proteins act as enzymes, complement components, protease inhibitors or kinin precursors.

The Chinese plasma protein market is heavily regulated and the market is characterized by supply shortages that provide lucrative opportunities to the leading companies operating in the sector. The main driving force of Plasma Proteins market in China is high demand of albumin in China, rapidly growing IVIG market, and rising expenditure on China healthcare sector.

Although, China Plasma Protein market is growing, there are some challenges that need to be addressed. These challenges include less expansion of Plasma Protein market, strict regulations such as ban on import of IVIG and FactorVIII and changes in China’s political and economic stability. Despite challenges like stringent regulations, ensuring adequate supply of human plasma and high cost of treatment in China Blood Plasma Proteins market, the Chinese IVIG market is all set to witness high growth in the coming years as a result of multiple factors such as growing ageing population, increasing number of patients with bleeding disorder and rising healthcare expenditure.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Executive Summary

2. Introduction to Plasma Protein Industry
2.1. History of Plasma Proteins Fractionation
2.2. Types of Plasma Proteins
2.2.1 Albumin
2.2.2 Intravenous Immunoglobulin (IGIV)
2.2.3 Factor VIII
2.2.4 A1PI
2.3. Clinical uses of Plasma Protein Products
2.4. Concept of Plasma Economics
2.5. Detailed Description of Plasma Collection Method
2.5.1 Plasma Collection
2.5.2 Plasma Extraction
2.5.3 Plasma Fractionation Yield
2.5.4 Plasma Usage
2.5.5 Steps to Assure Safe Plasma from Healthy Donors

3. Global Blood Plasma Market: Size and Growth (2010-2019)

4. China Plasma Protein Market: An Analysis
4.1 Chinese Plasma Protein Market Segmentation
4.1.1 Chinese Albumin Market: Actual and Forecast
4.1.2 Domestic Supply of Albumin in China: Actual & Forecast
4.1.3 Import of Albumin in China: Actual & Forecast
4.2 Chinese IVIG Market: Actual &Forecast
4.3 Chinese Factor VIII Market: Actual & Forecast

5. China Plasma Protein Market Share: An Analysis
5.1 China Blood Plasma Market Share: By Revenue
5.2 China Plasma Proteins Market Share: Segments
5.3 China Albumin Market Share: By Consumption
5.4 China Plasma Proteins Market Share: By Pharmaceutical Sales

6. China Plasma Protein Market: Facts and Statistical Analysis
6.1 China Plasma Protein Market Statistics Snapshot
6.2 China per Capita Expenditure on Medical Treatment
6.3 China Plasma Market Regulations

7. China Plasma Protein Market Dynamics
7.1 Growth Drivers
7.1.1 High Demand of Albumin
7.1.2 Rapidly Growing SCIG/IVIG Market
7.1.3 Rising China Healthcare Expenditure
7.1.4 GDP Growth in China
7.2 Market Trends
7.2.1 China Still at the Fast Growing Stage
7.2.2 Albumin Still Offers Opportunities for Exporters
7.2.3 High Entry Barriers for New Entrants Keep Supply Tight
7.3 Challenges
7.3.1 Less Expansion of Plasma Protein Market
7.3.2 Strict Regulations on China Plasma Proteins Market
7.3.3 Change in China’s Political or Economic Stability

8. Competitive Landscape: China Plasma Protein Market
8.1 China’s leading companies and their comparative analysis

9. Company Profiles: China Plasma Protein Market
9.1 China Biologic Product Inc.
9.1.1 Business Overview
9.1.2 Financial Overview
9.1.3 Business Strategies
9.2 Hualan Biological Engineering Inc.
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategies
9.3 Beijing Tiantan Biological Products Co. Ltd
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3 Business Strategies
9.4 Shanghai RAAS Blood Products Co. Ltd
9.4.1 Business Overview
9.4.2 Financial Overview
9.4.3 Business Strategy
9.5 CSL Ltd.
9.5.1 Business Overview
9.5.2. Financial Overview
9.5.3 Business Strategies

List of Figures

Figure 1: Composition of Blood Cells
Figure 2: Composition of Blood Plasma
Figure 3: Composition of Blood Plasma Proteins
Figure 4: Flow-Chart of Plasma Extraction
Figure 5: Steps to Assure Safe Plasma Collection from Healthy Donors
Figure 6: Global Blood Plasma Market-(US$ Billion)-2010-2014
Figure 7: Global Blood Plasma Market Forecast-(US$ Billion)-2015-2019
Figure 8: China Plasma Proteins Market-(US$ Billion)-2010-2014
Figure 9: Chinese Plasma Proteins Market Forecast-(US$ Billion)-2015-2019
Figure 10: China Albumin Market-(US$ Billion)-2010-2014
Figure 11: China Albumin Market Forecast-(US$ Billion)-2015-2019
Figure 12: Domestic Supply of Albumin in China-(Tonnes)-2010-2013
Figure 13: China Albumin Market Domestic Supply-(Tonnes)-2014-2019
Figure 14: China Albumin Market Import Supply-(Tonne) 2010-2013
Figure 15: China Albumin Market Import Supply-(Tonnes)-2014-2019
Figure 16: Chinese IVIG Market-(US$ Million)-2010-2014
Figure 17: Chinese IVIG Market Forecast-(US$ Million)-2015-2019
Figure 18: China FactorVIII Market- (US$ Million) -2010-2014
Figure 19: China FactorVIII Market Forecast-(US$ Million)-2015-2019
Figure 20: Blood Plasma Proteins Market Share-(Percentage)-2014
Figure 21: China Plasma Proteins Market Share-(Percentage)-2014
Figure 22: China Albumin Consumption Market Share-(Percentage)-2013
Figure 23: China Plasma Protein Market Share in China Pharmaceutical Market-(Percentage)-2013
Figure 24: China Plasma Protein Market Share in China Pharmaceutical Market (Percentage)-2014
Figure 25: China per Capita Expenditure on Medical Treatment- (USD)-2010-2014
Figure 26: China Healthcare Expenditure-2009-2013
Figure 27: GDP Growth Trend-(US$ Trillion)-2010-2014E
Figure 28: Comparative Analysis of China’s Leading Plasma Protein Companies – (US$ Million)-2014
Figure 29: Comparative Analysis of China’s Leading Plasma Protein Companies – (US$ Million)-2015E
Figure 30: Albumin Competitive Landscape in China-(Percentage)-2013
Figure 31: China Biologic Product Total Sales-(US$ Million)-2011-2014
Figure 32: Revenue Break-Up of China Biologic Product by Sales-(Percentage)-2014
Figure 33: Net Income of China Biologic Products-(US$ Million)-2011-2014
Figure 34: Expenditure in Research and Development-(US$ Million)-2011-2014
Figure 35: Hualan Biological Engineering Inc. Revenue-(US$ Million)-2010-2014
Figure 36: Hualan Biological Engineering Inc. Net income - (US$ Million)-2010-2014
Figure 37: Beijing Tiantan Biologic Products Co. Ltd. Revenue-(US$ Million)-2010-2014
Figure 38: Net Income of Beijing Tiantan Biological Products-(US$ Million)-2010-2014
Figure 39: Shanghai RAAS Blood Products Co. Ltd Revenue-(US$ Million)-2010-2014
Figure 40: Shanghai RAAS Blood Products Co. Ltd Net Income-(US$ Million)-2010-2014
Figure 41: Total Revenue of CSL Group- (US$ Billion)-2009-2013
Figure 42: Revenue Break-Up of CSL Group- (Geography)-2013
Figure 43: Net profit of CSL Ltd. - (US$ Million)-2009-2013
Figure 44: Expenditure in Research and Development – (US$ Million)-2009-2010

List of Tables

Table 1: Recovered Plasma versus Source Plasma
Table 2: Output per Litre of Plasma
Table 3: China Plasma Protein Market Statistics Snapshot
Table 4: China Plasma Regulations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Beijing Tiantan Biological Products Co. Ltd
- CSL Ltd.
- China Biologic Product Inc.
- Hualan Biological Engineering Inc.
- Shanghai RAAS Blood Products Co. Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll